2012 Fierce 15 member Celladon has boosted its IPO goals, seeking as much as $92 million to help get its gene therapy for heart failure through a Phase IIb study and into Phase III. The San Diego biotech plans to sell up to 5.8 million shares at between $14 and $16 apiece, raising its overall target from the $86.3 million it sought earlier this month. S-1